FATE THERAPEUTICS INC Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
FATE THERAPEUTICS INC (FATE) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 3.00 million shares for the 3-month period ending 2015-09-30, per its 10-Q filed 2016-11-07.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2016-11-07
- FATE THERAPEUTICS INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2015-09-30 was 3.00M shares, a 25.00% increase year-over-year.
- FATE THERAPEUTICS INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2015-06-30 was 2.90M shares, a 20.83% increase year-over-year.
- FATE THERAPEUTICS INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2015-03-31 was 3.00M shares, a 25.00% increase year-over-year.
- FATE THERAPEUTICS INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2014-09-30 was 2.40M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month |
|---|---|---|---|---|
| 2015-09-30 | 3.00M shares 10-Q · filed 2016-11-07 | 3.00M shares 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | 2.90M shares 10-Q · filed 2016-08-08 | 2.90M shares 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | 3.00M shares 10-Q · filed 2016-05-09 | |||
| 2014-09-30 | 2.40M shares 10-Q · filed 2015-11-03 | 2.40M shares 10-Q · filed 2015-11-03 | ||
| 2014-06-30 | 2.40M shares 10-Q · filed 2015-08-05 | 2.40M shares 10-Q · filed 2015-08-05 | ||
| 2014-03-31 | 2.40M shares 10-Q · filed 2015-05-07 | 2.20M shares 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |